Eftilagimod Alfa is a fusion protein commercialized by Immutep, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 24 clinical trials, of which 12 were completed, 5 are ongoing, 4 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Eftilagimod Alfa’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Eftilagimod Alfa is expected to reach an annual total of $915 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Eftilagimod Alfa Overview

Eftilagimod alfa (IMP-321, EDP-202) is under development for the treatment of HER2-negative hormone receptor-positive metastatic breast cancer, soft tissue sarcoma including undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, dedifferentiated liposarcoma (DDLPS), myxoid and round cell liposarcoma (MRCLPS), epithelioid sarcoma (ES), angiosarcoma (AS), peritoneal cancer, triple-negative breast cancer, non-small cell lung cancer, recurrent head and neck cancer squamous cell carcinoma, as an adjuvant therapy for metastatic melanoma, hepatocellular carcinoma, metastatic urothelial cancer and solid tumors. It is administered through subcutaneous, intratumoral and intraperitoneal routes. It is a recombinant soluble human lymphocyte-activation gene 3 (LAG-3) IgG Fc fusion protein. The drug candidate is developed by using ImmuFact technology.

The drug candidate was also under development for hepatitis B, pancreatic adenocarcinoma, unspecified influenza virus infection, metastatic renal cell carcinoma, coronavirus disease 2019 and prostate cancer.

Immutep Overview

Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company collaborates with pharmaceutical and biotech companies for research and development activities. It has operations in Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.
The company reported revenues of (Australian Dollars) AUD0.5 million for the fiscal year ended June 2022 (FY2022), an increase of 14.6% over FY2021. The operating loss of the company was AUD33.9 million in FY2022, compared to an operating loss of AUD20.7 million in FY2021. The net loss of the company was AUD32.2 million in FY2022, compared to a net loss of AUD29.9 million in FY2021.

For a complete picture of Eftilagimod Alfa’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.